Clinical trials: sponsored by Amgen
Asthma
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
- Trial name
- NCT06637371
- Testing
- AMG 691
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
The trial is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of AMG 691 in healthy Chinese and Japanese participants
- Trial name
- NCT07745907
- Testing
- AMG 691
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Amgen
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
The primary objective of the study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.
- Trial name
- NCT05481411
- Testing
- Olpasiran
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Amgen
Atopic Dermatitis
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.
- Trial name
- NCT06268860
- Testing
- Rocatinlimab vial injection, Rocatinlimab prefilled syringe
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Amgen
Basic Science
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
The primary objective of the study is: To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in…
- Trial name
- NCT06411860
- Testing
- Olpasiran, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Renal Impairment
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.
- Trial name
- NCT05489614
- Testing
- Olpasiran
- Where
- 6 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections
The primary objective of this trial is to evaluate the relative bioavailability of romosozumab administered as a single 2.34 mL subcutaneous (SC) injection from a prefilled syringe (PFS) or 2 x 1.17 mL SC injections from PFS in…
- Trial name
- NCT07811999
- Testing
- Romosozumab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Amgen
Cardiometabolic Disease
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
- Trial name
- NCT06585462
- Testing
- AMG 513
- Where
- 13 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
- Trial name
- NCT07545226
- Testing
- Evolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference)
- Where
- 4 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Amgen
End-Stage Renal Disease (ESRD)
A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
The primary objective of the study is to evaluate the pharmacokinetics (PK) of avacopan and metabolite (M1) after a single dose of avacopan in participants with normal renal function and participants with ESRD requiring…
- Trial name
- NCT06468826
- Testing
- Avacopan
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants, Pharmacokinetics
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
The main objective of this trial is to evaluate the pharmacokinetics of two evolocumab drug products in healthy participants.
- Trial name
- NCT07422285
- Testing
- Evolocumab Drug Substance A, Evolocumab Drug Substance B
- Where
- 4 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses.
- Trial name
- NCT06401044
- Testing
- AMG 732
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Amgen
Diabetes Mellitus, Type 2
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT07590193
- Testing
- AMG 127
- Where
- 2 sites in United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Amgen
Overweight and Obesity
A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered as a single subcutaneous (SC) dose using a liquid drug product in vial compared to a frozen liquid drug product in vial in…
- Trial name
- NCT07717814
- Testing
- AMG 133 (frozen liquid), AMG 133 (liquid)
- Where
- 4 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Amgen
Adalimumab
A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants
To determine the pharmacokinetic (PK) comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) compared to ABP 501 40 mg/0.8 mL (ABP 501-LCF) following single-dose subcutaneous (SC) injection, as assessed principally by area under the…
- Trial name
- NCT05909852
- Testing
- ABP 501-HCF, ABP 501-LCF
- Where
- 3 sites in United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Volunteers
Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
The main objective of the study is to assess the safety and tolerability of AMG 378 as single or multiple doses in healthy participants.
- Trial name
- NCT06910709
- Testing
- AMG 378
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amgen
Hepatic Impairment
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal…
- Trial name
- NCT07428525
- Testing
- AMG 133
- Where
- 5 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Volunteers
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.
- Trial name
- NCT07142642
- Testing
- Teprotumumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amgen
Overweight and Obesity
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.
- Trial name
- NCT07429045
- Testing
- AMG 133
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) [Lp(a)].
- Trial name
- NCT03626662
- Testing
- AMG 890
- Where
- 9 sites in United States, Australia
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Amgen